Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment.

Merck & Co Inc MRK and Eisai Co Ltd ESALY ESALF have provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating Keytuda plus Lenvima, in patients with certain types of metastatic ...

In the Phase 3 LEAP-012 trial, KEYTRUDA plus LENVIMA in combination with TACE reduced the risk of disease progression or death by 34% compared to TACE alone Late-breaking first interim analysis ...

But some analysts put estimates for Lenvima lower, with worldwide sales of the drug hitting $424 million by 2019. For comparison's sake, analysts see sales of Nexavar ringing in at $1.16 billion ...

Merck and Co. MRK along with its Japanese partner Eisai Co., Ltd. announced that the latter’s anti-cancer drug Lenvima has received approval in Japan for an expanded indication. The tyrosine ...